JP6509112B2 - オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法 - Google Patents

オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法 Download PDF

Info

Publication number
JP6509112B2
JP6509112B2 JP2015520652A JP2015520652A JP6509112B2 JP 6509112 B2 JP6509112 B2 JP 6509112B2 JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015520652 A JP2015520652 A JP 2015520652A JP 6509112 B2 JP6509112 B2 JP 6509112B2
Authority
JP
Japan
Prior art keywords
thiosulfate
sepsis
administered
composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015520652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523364A5 (enExample
JP2015523364A (ja
Inventor
プラブダ，ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015523364A publication Critical patent/JP2015523364A/ja
Publication of JP2015523364A5 publication Critical patent/JP2015523364A5/ja
Application granted granted Critical
Publication of JP6509112B2 publication Critical patent/JP6509112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7004—Stress
    • G01N2800/7009—Oxidative stress
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/206664—Ozone or peroxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015520652A 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法 Expired - Fee Related JP6509112B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261667719P 2012-07-03 2012-07-03
US61/667,719 2012-07-03
US201261691787P 2012-08-21 2012-08-21
US61/691,787 2012-08-21
US201361748698P 2013-01-03 2013-01-03
US61/748,698 2013-01-03
PCT/US2013/049087 WO2014008273A2 (en) 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Publications (3)

Publication Number Publication Date
JP2015523364A JP2015523364A (ja) 2015-08-13
JP2015523364A5 JP2015523364A5 (enExample) 2016-08-25
JP6509112B2 true JP6509112B2 (ja) 2019-05-08

Family

ID=49882592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520652A Expired - Fee Related JP6509112B2 (ja) 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法

Country Status (7)

Country Link
US (1) US20150174160A1 (enExample)
EP (1) EP2866565A4 (enExample)
JP (1) JP6509112B2 (enExample)
CN (1) CN104582490A (enExample)
AU (2) AU2013286876B2 (enExample)
CA (1) CA2915793A1 (enExample)
WO (1) WO2014008273A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210239678A1 (en) * 2018-04-19 2021-08-05 StickyCell Pty Ltd Leukocyte recruitment in infectious disease
US11406607B2 (en) 2018-05-24 2022-08-09 University Of Florida Research Foundation, Inc. Compositions, methods of treatment, and containers including compositions
AU2023312830A1 (en) * 2022-07-27 2025-02-20 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
JP2025531018A (ja) 2022-09-14 2025-09-19 ビオグノシス アーゲー 薬物標的滞留時間を決定し、最適な薬物－標的候補を選択する方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6712802B1 (en) * 1997-11-04 2004-03-30 Charles B. Cairns Metabolic therapy directed at electron transport
DK1063228T5 (da) * 1998-03-09 2009-06-15 Takeda Pharmaceutical Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
US20030190368A1 (en) * 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US7758893B2 (en) * 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
EP1302115A1 (fr) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Utilisation de cystathionine
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
WO2003104178A1 (en) * 2002-06-07 2003-12-18 Cortical Pty Ltd Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US20070270350A1 (en) * 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
EP2392321A1 (en) * 2007-06-13 2011-12-07 Jay Pravda Combined composition for rectal administration for the treatment of inflammatory bowel disease
WO2009154800A2 (en) * 2008-06-21 2009-12-23 Webb-Waring Institute Compositions and methods for treating lung disorders
CA2785633C (en) * 2009-12-28 2014-07-15 N.V. Perricone Llc Topical acyl glutathione formulations

Also Published As

Publication number Publication date
AU2017206229A1 (en) 2017-08-03
AU2013286876B2 (en) 2017-04-20
AU2013286876A1 (en) 2015-02-26
WO2014008273A3 (en) 2014-02-27
US20150174160A1 (en) 2015-06-25
EP2866565A4 (en) 2016-04-13
CA2915793A1 (en) 2014-01-09
JP2015523364A (ja) 2015-08-13
EP2866565A2 (en) 2015-05-06
CN104582490A (zh) 2015-04-29
WO2014008273A2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
Kolluru et al. Sulfide regulation of cardiovascular function in health and disease
Summar et al. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders
JP5303465B2 (ja) 液体カルコゲナイド組成物ならびにそれを製造および使用する方法
Wiliński et al. Metformin raises hydrogen sulfide tissue concentrations in various mouse organs
Hu et al. Pyruvate Ringer's solution corrects lactic acidosis and prolongs survival during hemorrhagic shock in rats
Rahman et al. The role of host-generated H2S in microbial pathogenesis: new perspectives on tuberculosis
WO2005017094A2 (en) N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
Luiking et al. A randomized-controlled trial of arginine infusion in severe sepsis on microcirculation and metabolism
AU2017206229A1 (en) Methods for treating, diagnosing and/or monitoring progression of oxo associated states
JP2010529197A5 (enExample)
Ingelfinger et al. Lactic acidosis
JPWO2017057768A1 (ja) 新規抗酸化眼内灌流液
Hohenfellner et al. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis
US20250325503A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
ES3035910T3 (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
Grünewald et al. Emergency diagnostic procedures and emergency treatment
CN102014891A (zh) 增加癌症患者存活时间的化合物的组合物和使用方法
Lorente et al. Perioperative fluid therapy in adults and children: a narrative review
Chiol├® ro et al. Nutritional support during renal replacement therapy
Katlan Methylene blue in metformin intoxication: not just rescue but also initial treatment
Besouw et al. Increased human dermal microvascular endothelial cell survival induced by cysteamine
Wingertzahn et al. Zinc as a potential enteroprotector in oral rehydration solutions: its role in nitric oxide metabolism
Hodgson et al. Acute arsenic exposure secondary to deliberate self-poisoning with sheep dip
US20080131525A1 (en) Therapeutic Nutrient Compositions Or Combinations And Methods Of Their Use
WO2023159060A1 (en) Compositions and methods for the treatment of coronavirus diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190402

R150 Certificate of patent or registration of utility model

Ref document number: 6509112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees